Cardiol Therapeutics (NASDAQ:CRDL)
- Number of Upgrades from Top-Ranked Analysts
- 7 (in the last 90 days)
- Consensus Rating
- Buy
- Rating Score
- 3.3
- Ratings Breakdown
- 7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $8.40 (805.6% Upside)
About Cardiol Therapeutics
Cardiol Therapeutics Inc, a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
More about Cardiol Therapeutics
Recent Analyst Ratings
